TY - JOUR
T1 - The value of circulating microRNAs for early diagnosis of B-cell lymphoma
T2 - A case-control study on historical samples
AU - Jørgensen, Steffen
AU - Paulsen, Isabella Worlewenut
AU - Hansen, Jakob Werner
AU - Tholstrup, Dorte
AU - Hother, Christoffer
AU - Sørensen, Erik
AU - Petersen, Mikkel Steen
AU - Nielsen, Kaspar Rene
AU - Rostgaard, Klaus
AU - Larsen, Margit Anita Hørup
AU - Brown, Peter de Nully
AU - Ralfkiær, Elisabeth
AU - Homburg, Keld Mikkelsen
AU - Hjalgrim, Henrik
AU - Erikstrup, Christian
AU - Ullum, Henrik
AU - Troelsen, Jesper
AU - Grønbæk, Kirsten
AU - Pedersen, Ole Birger
PY - 2020
Y1 - 2020
N2 - MicroRNAs are small regulatory RNAs that are deregulated in a wide variety of human cancers, including different types of B-cell lymphoma. Nevertheless, the feasibility of circulating microRNA for early diagnosis of B-cell lymphoma has not been established. To address the possibility of detecting specific circulating microRNAs years before a B-cell lymphoma is diagnosed, we studied the plasma expression of microRNA first in pre-treatment samples from patients with diffuse large B-cell lymphoma and subsequently in repository samples from blood donors who later developed B-cell lymphomas. In addition, we studied the microRNA expression in the diagnostic lymphoma biopsy. The most strongly induced (miR-326) and suppressed (miR-375) plasma microRNA at diagnosis, when compared with healthy blood donors, were also substantially up- or down-regulated in plasma repository samples taken from several months to up to two years before the blood donors were diagnosed with B-cell lymphoma. Importantly, at these time points the donors had no signs of disease and felt healthy enough to donate blood. In conclusion, this first study of plasma microRNA profiles from apparently healthy individuals, taken several years before B-cell lymphoma diagnosis, suggests that plasma microRNA profiles may be predictive of lymphoma development.
AB - MicroRNAs are small regulatory RNAs that are deregulated in a wide variety of human cancers, including different types of B-cell lymphoma. Nevertheless, the feasibility of circulating microRNA for early diagnosis of B-cell lymphoma has not been established. To address the possibility of detecting specific circulating microRNAs years before a B-cell lymphoma is diagnosed, we studied the plasma expression of microRNA first in pre-treatment samples from patients with diffuse large B-cell lymphoma and subsequently in repository samples from blood donors who later developed B-cell lymphomas. In addition, we studied the microRNA expression in the diagnostic lymphoma biopsy. The most strongly induced (miR-326) and suppressed (miR-375) plasma microRNA at diagnosis, when compared with healthy blood donors, were also substantially up- or down-regulated in plasma repository samples taken from several months to up to two years before the blood donors were diagnosed with B-cell lymphoma. Importantly, at these time points the donors had no signs of disease and felt healthy enough to donate blood. In conclusion, this first study of plasma microRNA profiles from apparently healthy individuals, taken several years before B-cell lymphoma diagnosis, suggests that plasma microRNA profiles may be predictive of lymphoma development.
U2 - 10.1038/s41598-020-66062-1
DO - 10.1038/s41598-020-66062-1
M3 - Journal article
C2 - 32541886
AN - SCOPUS:85086433900
VL - 10
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 9637
ER -